Ledger.Open graph →
SEC Form D · Amendment · filed April 18, 2022

Saliogen Therapeutics, Inc

Offering
$132.2M
Sold
$132.2M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (15)

Sean Stalfort · Cambridge, MADirectorCraig Gordon · Cambridge, MADirectorRaymond Tabibiazar · Cambridge, MAExec · DirectorSukumar Nagendran · Cambridge, MADirectorJoseph Higgins · Cambridge, MAExec · DirectorChris Darland · NEW YORK, NYExec · DirectorNicholas Jackson · NEW YORK, NYDirectorPatrick Horan · NEW YORK, NYDirectorCedarview GP, LLC · Woodmere, NYExec · DirectorTamanna Bembenek, Ph.D · NEW YORK, NYDirectorDevin Carty · Branford, CTExec · DirectorJason Baumgartner · Branford, CTDirectorYechuan Zhang · London, United KingdomDirectorRichard Skeet · London, United KingdomExec · DirectorMichael P. Brown Ii · Austin, TXDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗